A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

NCT04515849 on ClinicalTrials.gov · last registry update 2025-01-17

An unusually large phase 2: 248 participants, more than double the 110 typical for the stage. The sponsor logged completion for 8 March 2022. Primary outcome, as filed: The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks. semaglutide is already approved in the US for chronic kidney disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 248
Started: 2020-08-31
Primary completion: 2022-03-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks

Conditions studied

Type 2 Diabetes Mellitus · Chronic Kidney Diseases

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.